Tirzepatide vs Semaglutide: Which Is More Effective for Weight Loss and Diabetes? Meta Description:

Comparing Tirzepatide and Semaglutide

Tirzepatide and semaglutide (brand names Mounjaro and Ozempic/ Wegovy) are injectable medications used to treat type 2 diabetes and support weight loss. While both act on GLP-1 receptors, tirzepatide also targets GIP receptors, offering a broader hormonal impact.

 

Efficacy and Patient Outcomes

  • Weight Loss: In head-to-head trials (like SURPASS-2), tirzepatide consistently led to more significant weight loss than semaglutide.
  • A1C Reduction: Tirzepatide demonstrated slightly superior glycemic control.
  • Dosing: Semaglutide is available in weekly doses of up to 2.4 mg (Wegovy), while tirzepatide goes up to 15 mg

Both are effective and generally well-tolerated. The choice between them may depend on patient response, insurance coverage, and weight loss goals.

 

Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or adjusting any medication.

Back to blog